EGFR and neoplasm: Tumours harboring mutations in the RAS family (KRAS, NRAS, HRAS) result in constitutive activation of the MAPK signalling pathway, and are unlikely to benefit from treatment with epidermal growth factor receptor (EGFR) antibodies [117].